Mixed
Briakinumab: reduce relapses and new lesions in MS (type not specified)
MS (type not specified) · T-cell co-stimulation / cytokine targeting
Controlled trials disagree.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 215
Human genetics
Genes linked to MS that these medicines act on: IL12A, IL12B
How the verdict was reached
Mixed phase 2 results
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Briakinumab, phase 2 | Phase 2 | 215 | 2004 | Mixed result At week 24, gadolinium-enhanced lesions were statistically significantly reduced with ABT-874 200 mg EOW vs. placebo (mean number [SD]: 5.4 [8.1] vs. 7.6 [14.4], p = 0.003), but not with ABT-874 200 mg EW (6.8 [11.3], p = 0.134). Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Results pending to Mixed
- Oct 2026First listed as Results pending
Related hypotheses
Assembled by software from public sources.